Status:
COMPLETED
Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Ulcerative Colitis
Flare Up, Symptom
Eligibility:
All Genders
Brief Summary
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerati...
Detailed Description
Ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab were identified. The investigators performed a retrospective chart review and assessed patient reported outcomes and ...
Eligibility Criteria
Inclusion
- Patient of the Swiss IBD cohort study
- Diagnosis of ulcerative colitis
- Past treatment with golimumab (at least one dose)
Exclusion
- none
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT05405465
Start Date
January 1 2018
End Date
June 1 2021
Last Update
June 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Gastroenterology, University Hospital Zurich
Zurich, Switzerland, 8091